XML 38 R1.htm IDEA: XBRL DOCUMENT v3.26.1
Document and Entity Information - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2025
Feb. 28, 2026
Jun. 30, 2025
Document Information [Line Items]      
Document Type 10-K    
Amendment Flag false    
Document Period End Date Dec. 31, 2025    
Document Annual Report true    
Document Fiscal Year Focus 2025    
Document Fiscal Period Focus FY    
Entity Registrant Name AARDVARK THERAPEUTICS, INC.    
Central Index Key 0001774857    
Entity File Number 001-42513    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 82-1606367    
Entity Address, Address Line One 4370 La Jolla Village Drive    
Entity Address, Address Line Two Suite 1050    
Entity Address, City or Town San Diego    
Entity Address, State or Province CA    
Entity Address, Postal Zip Code 92122    
City Area Code 858    
Local Phone Number 225-7696    
Document Transition Report false    
Entity Well-known Seasoned Issuer No    
ICFR Auditor Attestation Flag false    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Document Financial Statement Error Correction [Flag] false    
Documents Incorporated by Reference

None.

    
Current Fiscal Year End Date --12-31    
Entity Public Float     $ 162.9
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company true    
Entity Ex Transition Period false    
Entity Shell Company false    
Entity Common Stock, Shares Outstanding   21,816,041  
Title of 12(b) Security Common Stock, par value $0.00001 per share    
Trading Symbol AARD    
Security Exchange Name NASDAQ    
Auditor Name BDO USA, P.C    
Auditor Firm ID 243    
Auditor Location San Diego, California    
Auditor Opinion

Opinion on the Consolidated Financial Statements

We have audited the accompanying consolidated balance sheets of Aardvark Therapeutics, Inc. (the “Company”) as of December 31, 2025 and 2024, the related consolidated statements of operations and comprehensive loss, convertible preferred stock and stockholders’ equity (deficit), and cash flows for the years then ended, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2025 and 2024, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.